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Acid-Base Disorders
Objectives After completing this article, readers should be able to:
1. Understand the mechanisms for regulating acid-base physiology. 2. Know the differential diagnosis of metabolic acidosis associated with high anion gap and plan for initial management. 3. Know the differential diagnosis of normal anion gap metabolic acidosis. 4. Describe pulmonary compensatory changes in metabolic acidosis and alkalosis. 5. Understand how various diuretics can lead to acid-base imbalance. 6. Describe renal compensatory changes in respiratory acidosis and alkalosis.
Case Study
A 16-year-old girl who has no significant previous medical history presents to the emergency department with a 4-day history of nausea, vomiting, fever, chills, diarrhea, leg cramps, abdominal pain, and 
Introduction
The loss of acid-base balance is an expression of various conditions encountered frequently in clinical practice. Changes in hydrogen ion concentration can lead to unraveling of the protein tertiary structure, thereby causing enzyme dysfunction, enzyme loss, and cell death. Understanding the physiology behind various disturbances in acid-base balance is necessary for determining a correct diagnosis and management plan. Maintaining acid-base homeostasis involves the lungs, kidneys, and a very complex system of buffers, all aiming to maintain the normal pH (7.35 to 7.45) of the arterial blood. Lowering the arterial pH below 7.35 is termed acidosis, and an increase of the arterial pH above 7.45 constitutes alkalosis.
Metabolic acidosis is associated with a low pH and low HCO 3 Ϫ concentration. Metabolic alkalosis is associated with a high pH and high HCO 3 Ϫ concentration. Respiratory acidosis is associated with a low pH and high PCO 2 . Respiratory alkalosis is associated with a high pH and low PCO 2 (Fig. 1) .
Each acid-base disorder leads to countering respiratory or renal compensatory responses that attempt to normalize the pH. In metabolic acidosis, for example, ventilation is increased, resulting in a decrease in PCO 2 , which tends to raise the pH toward normal. These compensatory attempts never overshoot correcting the pH (Figs. 2 and 3) .The process of acid-base regulation involves the respiratory system (controls PCO 2 ), kidneys (regulates plasma HCO 3 Ϫ by changes in acid excretion), and a very complex system of extracellular and intracellular buffers.
The Respiratory System in Acid-Base Balance
The respiratory system contributes to acid-base balance via timely adjustments in alveolar minute ventilation that maintain systemic acid-base equilibrium in response to alterations in systemic pH and arterial PCO 2 . Systemic pH is monitored by central chemoreceptors on the ventrolateral surface of the medulla oblongata and arterial PCO 2 (as well as arterial PO 2 ) by peripheral chemoreceptors located at the carotid and aortic bodies. These chemoreceptors act through central respiratory control centers in the pons and medulla to coordinate the respiratory muscle efforts of inhalation and exhalation, leading to adjustments in both components of minute ventilation: tidal volume and respiratory cycle frequency. Lung-mediated changes in arterial PCO 2 can lead to rapid alteration in systemic hydrogen ions (H ϩ ) because CO 2 is lipidsoluble and may readily cross cell membranes according to the following equation: H ϩ ϩ HCO 3 Ϫ 7H 2 CO 3 (carbonic acid)7CO 2 ϩ H 2 O (water). Under normal physiologic conditions, this process allows for tight control of arterial PCO 2 near 40 mm Hg. 
The Kidneys in Acid-Base Balance
The kidney's role in acid-base balance consists of reabsorbing filtered HCO 3 Ϫ and excreting the daily acid load derived principally from the metabolism of sulfurcontaining amino acids. Ninety percent of filtered HCO 3 Ϫ is reabsorbed in the proximal tubules, primarily by Na ϩ -H ϩ exchange, and the remaining 10% is reabsorbed in the distal nephron, primarily via hydrogen secretion by a proton pump (H ϩ -ATPase). Under normal conditions, no HCO 3 Ϫ is present in the final urine. The excretion of the daily H ϩ load occurs in the distal tubule. Once excreted in the urine, the H ϩ must be bound to a buffer to avoid excessive urine acidification and promote further excretion. The two primary buffers in the urine are ammonia (NH 3 ), which is excreted and measured as ammonium (NH 4 ϩ ) and phosphate (referred to and measured as titratable acidity). The kidneys synthesize and excrete NH 3 , which combines with H ϩ excreted by the collecting duct cells to form NH 4 ϩ : H ϩ ϩNH 3 ϭNH 4 ϩ . NH 3 diffuses freely across membranes; NH 4 ϩ does not. Failure to produce and excrete sufficient NH 4 ϩ , therefore, leads to the development of metabolic acidosis.
Extracellular and Intracellular Buffers in Acid-Base Balance
The most important buffer in the extracellular fluid is HCO 3 Ϫ , due both to its relatively high concentration and its ability to vary PCO 2 via changes in alveolar ventilation. Chemoreceptor analysis of arterial pH and PCO 2 allows for centrally mediated adjustments in minute ven- Ϫ as independent predictors of acid-base balance, but in reality they are interdependent (as suggested by the chemical reaction H ϩ ϩ HCO 3 Ϫ described previously). Furthermore, the Henderson-Hasselbalch equation does not account for other important nonbicarbonate buffers present in the body, such as the primary intracellular buffers of proteins, organic and inorganic phosphates, and hemoglobin. In addition, bone is an important site for buffering of acid and base loads.
Laboratory Assessment of Acid-Base Balance
Acid-base balance is assessed by blood gas analysis and serum measurement of several important electrolytes, leading to the calculation of the AG. Blood gas analyzers measure the pH and the PCO 2 directly. The HCO 3 Ϫ value is calculated from the Henderson-Hasselbalch equation. The BE value also is calculated as the amount of base/acid that should be added to a sample of whole blood in vitro to restore the pH to 7.40 while the PCO 2 is held at 40 mm Hg. The PCO 2 not only points to the type of disorder (respiratory or metabolic) but also corresponds to the magnitude of the disorder.
The AG method was developed to include other nonbicarbonate buffers in the analysis. Based on the principle of electroneutrality, the sum of the positive charges should equal the sum of the negative charges as follows:
Ϫ . Sodium, chloride, and HCO 3 Ϫ are measured easily in the serum. Therefore, the AG is calculated by the formula AGϭ{Na ϩ } Ϫ {Cl Ϫ ϩ HCO 3 Ϫ }. A normal AG is 12Ϯ2 mEq/L (12 mmol/L). Some clinicians and some published reports include potassium as a measured cation in the calculation of AG, which raises the normal value by 4 mEq/L (4 mmol/L).
The AG is defined as the difference between the unmeasured plasma anions and the unmeasured plasma cations. Clinically, an elevated AG is believed to reflect an increase of unmeasured anions and, therefore, a metabolic acidosis. This concept is explained by the fact that unmeasured cations (Mg 2ϩ ϩ Ca 2ϩ ϩ H ϩ ) are more fluids and electrolytes acid-base disorders tightly controlled and the unmeasured anions have a greater tendency to fluctuate. Theoretically, the AG also can increase following a decrease in serum K ϩ , Ca 2ϩ , or Mg 2ϩ , but the normal concentration of these cations is so low that a reduction does not have a significant clinical impact on the AG.
In general, these principles hold true for the previously healthy individual who develops an acute illness. However, for the critically ill host whose plasma protein concentrations are greatly reduced, the low protein values hide an associated increase in unmeasured anions. Without the correction for hypoalbuminemia, it is possible to overlook a true high AG acidosis, mistakenly assuming it to be a normal AG acidosis.
According to the Figge formula, each 1-g/dL reduction in the serum albumin concentration is expected to reduce the AG by 2.5 mEq/L:
Metabolic Acid-Base Disturbance Metabolic Acidosis
Metabolic acidosis is defined as an acid-base imbalance that leads to anion excess (low HCO 3 Ϫ concentration) and subsequently to an arterial pH below 7.35. Several mechanisms can lead to metabolic acidosis: excess acid production, increased acid intake, decreased renal acid excretion, increased HCO 3 Ϫ loss from the gastrointestinal (GI) tract, and excess HCO 3 Ϫ excretion in the kidney. For a patient who has intact respiratory function, developing metabolic acidosis leads to respiratory compensation by hyperventilation. Each 1-mEq/L reduction in plasma HCO 3 Ϫ concentration prompts a 1.2-mm Hg compensatory fall in the PCO 2 . Clinically, the patient's respiratory rate increases within the first hour of the onset of metabolic acidosis, and respiratory compensation is achieved within 24 hours. Failure of the respiratory system to compensate for metabolic acidosis is an ominous sign that should trigger careful evaluation of the patient's mental status and cardiorespiratory function.
Calculating the AG is a very useful initial step in diagnosing various causes of metabolic acidosis.
Metabolic Acidosis With Normal Anion Gap
Metabolic acidosis with normal AG reflects an imbalance of the measured plasma anions and cations. According to the formula: AGϭNa ϩ Ϫ (Cl Ϫ ϩ HCO 3 Ϫ ), metabolic acidosis with normal AG can be explained by excessive loss of HCO 3 Ϫ (in the stool or in the urine) or by inability to excrete hydrogen ions. Table 1 lists the most frequent conditions leading to normal AG metabolic acidosis.
Of particular note is renal tubular acidosis (RTA), a complex set of disorders of the kidney that can lead to normal AG metabolic acidosis. One disorder is the inability to excrete the daily acid load (type 1 RTA), leading to progressive H ϩ ion retention and low plasma HCO 3
. Another disorder arises from the inability to reabsorb HCO 3 Ϫ normally in the proximal tubule (proximal RTA or type 2 RTA). HCO 3 Ϫ is lost in the urine despite some reabsorption in the distal nephron, leading to metabolic acidosis and alkaline urine.
Normal AG metabolic acidosis caused by excessive HCO 3 Ϫ losses may be corrected by slow infusion of sodium bicarbonate-containing intravenous fluids.
Elevated Anion Gap Metabolic Acidosis
Elevated AG metabolic acidosis results from an excess of unmeasured anions. Various conditions that cause an Table 2 .
When faced with an elevated AG metabolic acidosis, calculating the osmotic gap may help determine the underlying condition. Similar to the AG, the osmotic gap is the difference between the measured serum osmolality and the calculated value. The calculated serum osmolality is: 2 ϫ [Na ϩ ] ϩ glucose/18 ϩ BUN/2.8. A normal osmotic gap should be 12Ϯ2 mOsm/L. A high osmotic gap is a sign of an excess of an unmeasured osmotic active substance such as ethylene glycol (antifreeze), methanol (wood alcohol), or paraldehyde.
Ketoacidosis
Ketoacidosis describes accumulation of ketone bodies (beta-hydroxybutyrate and acetoacetic acid) following excessive intracellular use of lipids as a metabolic substrate. This metabolic shift occurs during starvation or fasting or as a reflection of a lack of appropriate metabolic substrate for energy production (during specific diets where carbohydrates are replaced with lipids). Hyperketotic diets sometimes are employed for intractable epilepsy in an effort to decrease the seizure threshold.
Diabetic ketoacidosis (DKA) results from a decrease in insulin production that leads to an inability to transport glucose into the cell. The cell shifts to lipid metabolism, despite the surrounding hyperglycemia (also described as "starvation in the middle of the plenty"). The diagnosis of DKA is confirmed by the findings of hyperglycemia, a high AG acidosis, ketonuria, and ketonemia.
The earliest symptoms of DKA are related to hyperglycemia. Older children and adolescents typically present with polyuria (due to the glucose-induced osmotic diuresis), polydipsia (due to the increased urinary losses), fatigue, and weight loss. Hypovolemia may be severe if urinary losses are not replaced, with the presentation of very dry mucous membranes and prolonged capillary refill time. As a result of worsening metabolic acidosis, the patient develops hyperventilation and deep (Kussmaul) respirations, representing respiratory compensation for metabolic acidosis. Hyperpnea develops from an increase in minute volume (rate ϫ tidal volume) or from increased tidal volume alone without an increase in respiratory rate. When DKA is being managed, the patient's chest excursion and respiratory rate should be observed carefully to determine if hyperpnea is present. In infants, hyperpnea may be manifested only by tachypnea.
Without prompt medical attention, DKA can progress to cerebral edema and cardiorespiratory arrest. Neurologic findings, ranging from drowsiness, lethargy, and obtundation to coma, are related to the severity of hyperosmolality or to the degree of acidosis. Treatment of DKA includes sensitive correction of the underlying insulin, volume, and electrolyte deficiencies.
Lactic Acidosis
Lactic acidosis, another cause of an elevated AG, occurs when cells shift to anaerobic pathways for energy production as a result of tissue hypoxia due to inappropriate tissue perfusion, inappropriate oxygen supply, or mitochondrial dysfunction (as seen in inborn errors of metabolism or ingestion of drugs or toxins). The clinical presentation may involve seizures or symptoms consistent with the initial disorder that led to lactic acidosis, such as cyanosis, signs and symptoms suggestive of tissue hypoperfusion, and hypotension. As lactic acidosis worsens, further hemodynamic compromise occurs. Management should be targeted to restoring adequate tissue perfusion and oxygen supply by treating the underlying cause of the lactic acidosis.
Inborn Errors of Metabolism
Several inborn errors of metabolism can present with high AG metabolic acidosis. Based on the affected metabolic pathway, the increased AG is caused by a different chemical substance: urea cycle defects present with hyperammonemia; or inborn errors of amino acids, carbohydrate, or organic acid metabolism present either with ketoacidosis, lactic acidosis (as in Krebs cycle defects), or increased organic acids production. Symptoms often are nonspecific and include poor feeding, failure to thrive, seizures, and vomiting. Managing inborn errors of metabolism involves identifying the defective or deficient enzyme and limiting the intake of the metabolic substrate that requires the use of that particular enzyme. In selected cases, dialysis may be the appropriate tool for removing the excess anion.
Ingestions
Ingestions of various chemical substances are another cause of metabolic acidosis with an elevated AG. Salicylate overdose is well known to cause increased AG metabolic acidosis by interfering with cellular metabolism (uncoupling of oxidative phosphorylation). Early symptoms of salicylate overdose include tinnitus, fever, vertigo, nausea, vomiting, and diarrhea. More severe intoxication can cause altered mental status, coma, noncardiac pulmonary edema, and death. Most patients show signs of intoxication when the plasma salicylate concentration exceeds 40 mg/dL. Treatment of salicylate ingestion involves promoting alkaline diuresis to enhance renal salicylate excretion. In severe cases, dialysis may be required (generally considered when plasma salicylate concentrations exceed 80 mg/dL in acute intoxication and 60 mg/dL in chronic ingestions).
Toluene inhalation also can lead to metabolic acidosis with an increased AG. In patients who experience toluene ingestion (glue sniffing), the overproduced hippurate is both filtered and secreted by the kidneys, leading to rapid elimination in the urine. As a result, the AG may be near-normal or normal at the time of presentation and the patient might be diagnosed mistakenly as having a normal AG acidosis.
Ethylene glycol (antifreeze), methanol, and paraldehyde ingestion lead to an increased AG metabolic acidosis and an increased osmotic gap. Both the AG and the acidosis due to methanol and ethylene glycol ingestions result from metabolism of the parent compound. Neither may be seen in patients early in the course of ingestion or when there is concurrent ingestion of ethanol. Ethanol combines competitively with alcohol dehydrogenase, thereby slowing the metabolism of methanol or ethylene glycol to their toxic metabolites and slowing the appearance of both the acidosis and the high AG. This effect explains why ethanol administration is used in the medical management of methanol and ethylene glycol ingestions, along with fomepizole (alcohol dehydrogenase inhibitor). Management of ethylene glycol and methanol toxicity also involves hemodialysis, which removes both the ingested substance and the metabolic byproducts from the serum.
Massive ingestions of creams containing propylene glycol (eg, silver sulfadiazine) also can lead to increased AG metabolic acidosis.
Renal Failure
Renal failure causes an increased AG metabolic acidosis due to the failure to excrete H ϩ . Normally, elimination of the serum acid load is achieved by urinary excretion of H ϩ , both as titratable acidity and as NH 4 ϩ . Titratable acid is a term used to describe acids such as phosphoric acid and sulfuric acid present in the urine. The term explicitly excludes NH 4 ϩ as a source of acid and is part of the calculation for net acid excretion. The term titratable acid was chosen based on the chemical reaction of titration (neutralization) of those acids in reaction with sodium hydroxide.
As the number of functioning nephrons declines in chronic kidney disease and the glomerular filtration rate decreases to below 25% of normal, the patient develops progressive high AG metabolic acidosis (hyperchloremia may occur transiently in the initial phases of renal failure). In addition to the decrease in NH 4 ϩ excretion, decreased titratable acidity (primarily as phosphate) may play a role in the pathogenesis of metabolic acidosis in patients who experience advanced kidney disease. Of course, dialysis often is employed to correct the severe fluid and electrolyte imbalances generated by renal failure.
Management of Metabolic Acidosis
Regardless of the cause, acidemia, if untreated, can lead to significant adverse consequences (Table 3) .
Use of HCO 3 Ϫ therapy to adjust the pH for patients who have metabolic acidosis is controversial. Slow infusion of sodium bicarbonate-containing intravenous fluids can be used in cases of normal AG metabolic acidosis to replenish excessive HCO 3 Ϫ losses (eg, as a result of excessive diarrhea). However, infusing sodium bicarbonate-containing fluids for increased AG metabolic acidosis has questionable benefit and should not be used clinically.
As discussed, HCO 3 Ϫ combines with H ϩ , leading to H 2 CO 3 that subsequently dissociates to CO 2 and H 2 O. Infusing HCO 3 Ϫ decreases serum pH and raises CO 2 and H 2 O. Neither the cell membranes nor the blood-brain barrier is very permeable to HCO 3 Ϫ ; CO 2 diffuses freely to the intracellular space, where it combines with H 2 O, leading to H 2 CO 3 and worsening of the intracellular pH. Administering intravenous sodium bicarbonate to a patient who has an increased AG metabolic acidosis can lead to a false sense of security because the underlying problem is hidden by an artificially improved serum pH.
fluids and electrolytes acid-base disorders
Sodium bicarbonate once held a prominent position in the management of cardiac arrest. Reversing the acidosis caused by global hypoperfusion made physiologic sense because severe acidemia may worsen tissue perfusion by decreasing cardiac contractility. However, the most effective means of correcting the acidosis in cardiac arrest is to restore adequate oxygenation, ventilation, and tissue perfusion. Because most pediatric cardiac arrests are due to respiratory failure, support of ventilation through early intubation is the primary treatment, followed by support of the circulation with fluids and inotropic agents. Currently, the American Heart Association recommends that sodium bicarbonate administration be considered only in children who suffer prolonged cardiac arrest and documented severe metabolic acidosis and who fail to respond to oxygenation, ventilation, intravenous fluids, and chest compressions combined with epinephrine in recommended doses.
Metabolic Alkalosis
Metabolic alkalosis is defined as an acid-base imbalance leading to increased plasma HCO 3 Ϫ and an arterial pH above 7.45. Several mechanisms can lead to the elevation in the plasma HCO 3 Ϫ : excessive hydrogen loss, functional addition of new HCO 3 Ϫ , and volume contraction around a relatively constant amount of extracellular HCO 3 Ϫ (called a "contraction alkalosis"). The kidneys are extremely efficient in eliminating excess HCO 3 Ϫ in the urine. A confounding factor is required for serum HCO 3 Ϫ to accumulate, such as impaired renal function, K ϩ depletion, or volume depletion. In general, a patient compensates for a metabolic alkalosis by decreasing ventilation. Respiratory compensation by hypoventilation raises PCO 2 by 0.7 mm Hg for every 1 mEq/L (1 mmol/L) of serum HCO 3 Ϫ increase. Excessive H ϩ losses can occur either in the urine or GI tract and lead to HCO 3 Ϫ accumulation as the result of the following reactions:
Increased loss of gastric content, which has high concentrations of hydrogen chloride, as a result of persistent vomiting (eg, self-induced, pyloric stenosis) or high nasogastric tube drainage leads to metabolic alkalosis. If fluid losses continue unreplaced, dehydration and lactic acidosis ultimately develop. Of note, infants of mothers who have bulimia have metabolic alkalosis at birth.
High H ϩ loss in the urine can occur in the distal nephron. Increased secretion of aldosterone stimulates the secretory H-ATPase pump, increasing Na ϩ reabsorption, thereby making the lumen more electronegative and causing more H ϩ and K ϩ excretion, which results in concurrent metabolic alkalosis and hypokalemia. Patients who have primary mineralocorticoid excess present with hypokalemia and hypertension. In contrast, secondary hyperaldosteronism due to congestive heart failure or cirrhosis usually does not present with metabolic alkalosis or hypokalemia because the above-mentioned mechanism is blunted by decreased distal nephron Na ϩ delivery. Iatrogenic metabolic alkalosis along with volume contraction can occur in patients treated with loop or thiazide diuretics, which cause Cl Ϫ depletion and increased delivery of Na ϩ to the collecting duct, which enhances K ϩ and H ϩ secretion. Bartter and Gitelman syndromes present with metabolic alkalosis and hypokalemia due to a genetic defect in the transporters in the loop of Henle and distal tubule, respectively, the same locations as those inhibited by loop and thiazide diuretics. In addition to H ϩ loss, metabolic alkalosis also can be induced by the shift of H ϩ into the cells. As discussed previously, hypokalemia is a frequent finding in patients who have metabolic alkalosis. Hypokalemia by itself causes intracellular acidosis and increased serum alkalosis by the following mechanism: intracellular K ϩ shifts into the serum to replete the extracellular stores, and to maintain electroneutrality, H ϩ enters the cells. Hydrogen movement into the cells lowers the intracellular pH and leaves unbuffered excess HCO 3 Ϫ in the serum. The intracellular acidosis in renal tubular cells promotes H ϩ secretion and, therefore, HCO 3 Ϫ reabsorption. Metabolic alkalosis due to functional addition of "new" HCO 3 Ϫ can occur by several mechanisms: decreased renal excretion of HCO 3 Ϫ , posthypercapnic alkalosis, or excessive intake or administration of alkali.
Decreased Renal Bicarbonate Excretion
Renal failure can lead to metabolic alkalosis because the kidneys fail to excrete excess HCO 3 Ϫ .
Posthypercapnic Alkalosis
Chronic respiratory acidosis (retention of CO 2 ) leads to a compensatory increase in hydrogen secretion and an ensuing increase in the plasma HCO 3 Ϫ concentration to correct the pH. When the PCO 2 is decreased rapidly by mechanical ventilation of a patient who has chronic respiratory acidosis, the ensuing metabolic alkalosis is slow to disappear. Because Cl Ϫ loss often is present in posthypercapnic alkalosis, repleting the Cl Ϫ deficit may be essential to correct the alkalosis.
Furthermore, the acute fall in PCO 2 in a person who has chronic respiratory acidosis raises the cerebral intracellular pH acutely, a change that can induce serious neurologic abnormalities and death because CO 2 can diffuse freely across the blood-brain barrier out of the intracellular space, leading to severe alkalosis. Accordingly, the PCO 2 must be reduced gradually in mechanically ventilated patients who present initially with chronic hypercapnia.
Excessive Intake or Administration of Alkali
Alkali administration does not induce metabolic alkalosis in healthy people because the healthy kidney can excrete HCO 3 Ϫ rapidly in the urine. However, metabolic alkalosis can occur if very large quantities of HCO 3 Ϫ are administered acutely or if the ability to excrete HCO 3 Ϫ is impaired. The administration of large quantities of citrate is known to lead to metabolic alkalosis. Examples of large administrations of citrate are infusion of more than 8 units of banked blood or fresh frozen plasma or administration of citrate as an anticoagulant during dialysis.
Contraction Alkalosis
Contraction alkalosis occurs when relatively large volumes of HCO 3 Ϫ -free fluid are lost, a situation frequently seen with administration of intravenous loop diuretics. Contraction alkalosis also may occur in other disorders in which a high-Cl Ϫ , low-HCO 3 Ϫ solution is lost, such as sweat losses in cystic fibrosis, loss of gastric secretions in patients who have achlorhydria, and fluid loss from frequent stooling by patients who have congenital chloridorrhea, a rare congenital secretory diarrhea.
Regardless of the cause, alkalosis, if untreated, can lead to significant adverse consequences (Table 4) .
Management of Metabolic Alkalosis
Three general principles apply to the therapy of metabolic alkalosis: correct true volume depletion, correct K ϩ depletion, and correct Cl Ϫ depletion (in Cl Ϫ -responsive metabolic alkalosis). For patients who have true volume depletion, fluid administration of normal saline replaces the Cl Ϫ and free water deficits. Potassium chloride administration for patients who have concurrent hypokalemia is an important component of treatment. This agent becomes particularly helpful in patients who are edematous due to heart failure or cirrhosis and cannot receive sodium chloride because an infusion can increase the degree of edema. Another method for treating metabolic alkalosis in an edematous patient is to administer acetazolamide, a carbonic anhydrase inhibitor, which causes a mild increase in production of urine that has high HCO 3 Ϫ content, thus reacidifying the blood. Correcting metabolic alkalosis (usually diureticinduced) may be particularly important for intubated patients who have chronic respiratory acidosis. The higher pH caused by the metabolic alkalosis subsequently impairs the respiratory drive and leads to hypoventilation that exacerbates hypoxemia, delaying weaning and extubation. In these patients, metabolic alkalosis usually is corrected by enteral supplements of potassium chloride or sodium chloride. Very rarely, in the intensive care unit setting, the metabolic alkalosis can be so severe that it impairs weaning from mechanical ventilation. In these circumstances, intravenous infusion of hydrogen chloride can correct the alkalosis.
Measuring the urinary Cl Ϫ is the preferred method for assessing the renal response to Cl Ϫ therapy. For patients experiencing Cl Ϫ depletion (urinary Cl Ϫ Ͻ10 mEq/L [10 mmol/L]) (eg, GI losses, diuretic therapy, and sweat losses in cystic fibrosis), every attempt should be made to correct hypochloremia. Conditions that cause metabolic alkalosis due to high aldosterone concentrations are unresponsive to Cl Ϫ and are associated with high urine Cl Ϫ concentrations.
Minimizing continuing acid and chloride losses by excessive nasogastric fluid drainage with a histamine 2 blocker or proton pump inhibitor also may be helpful.
Respiratory Acid-Base Disturbances
As noted, chemoreceptor analysis of arterial pH and PCO 2 allows for centrally mediated adjustments in minute ventilation to maintain arterial PCO 2 near 40 mm Hg. Primary respiratory disturbances in acid-base equilibrium may result from different pathologic scenarios. Arterial PCO 2 rises abnormally (respiratory acidosis) if systemic CO 2 production exceeds the ventilatory capacity or when efficient ventilation is inhibited by intrinsic or acquired conditions. Conversely, arterial PCO 2 decreases abnormally (respiratory alkalosis) in response to physiologic disorders that result in excessive ventilation. Both respiratory acidosis and alkalosis may appear in association with other metabolic acid-base disturbances, often making accurate diagnosis and treatment of the underlying disease difficult to achieve.
Respiratory Acidosis
Respiratory acidosis occurs when arterial PCO 2 increases and arterial pH decreases due to a reduction in alveolar minute ventilation or, less commonly, an excessive increase in CO 2 production. Acute respiratory acidosis occurs with an acute elevation in PCO 2 as a result of sudden limitation or failure of the respiratory system. Chronic respiratory acidosis is due to more indolent increases in PCO 2 as a consequence of systemic disease over the course of several days. Reduction in minute ventilation can result from depression of central nervous system (CNS) respiratory drive, anatomic obstruction of the respiratory tract, or intrinsic or acquired impairments of normal thoracic excursion (Table 5) . 
Management of Respiratory Acidosis
Treatment of respiratory acidosis usually focuses on correcting the primary disturbance. Immediate discontinuation of medications that suppress central respiratory drive or administration of appropriate reversal agents should be considered. Noninvasive ventilation or intubation with mechanical ventilation may be necessary to achieve adequate alveolar ventilation and appropriate reduction in arterial PCO 2 . As arterial PCO 2 is corrected, individuals who experience excessive Cl Ϫ depletion may subsequently suffer poor renal clearance of HCO 3 Ϫ , leading to a concomitant state of metabolic alkalosis.
Respiratory Alkalosis
Respiratory alkalosis occurs when there is reduction in arterial PCO 2 and elevation in arterial pH due to excessive alveolar ventilation. Causes of excessive alveolar ventilation include medication toxicity, CNS disease, intrinsic lung diseases, and hypoxia (Table 6) .
Compensatory changes in response to respiratory alkalosis involve renal excretion of HCO 3 . As in respiratory acidosis, renal compensation improves as the disorder persists. Serum HCO 3 Ϫ concentrations decline by 2 mEq/L (2 mmol/L) for every 10-mm Hg decrease in arterial PCO 2 in acute respiratory alkalosis. In chronic respiratory alkalosis, serum HCO 3 Ϫ concentrations decline by 4 mEq/L (4 mmol/L) for every 10-mm Hg decrease in arterial PCO 2 .
Adverse Effects of Respiratory Alkalosis
Adverse systemic effects of respiratory alkalosis include CNS and cardiovascular disturbances. Respiratory alkalosis often provokes increased neuromuscular irritability, manifested as paresthesias or carpopedal spasms. In addition, cerebral blood vessels vasoconstrict acutely and impede adequate cerebral blood flow. Myocardial contractility may be diminished and cardiac arrhythmias may occur. The oxyhemoglobin dissociation curve shifts to the left in response to acute respiratory alkalosis, impairing peripheral oxygen delivery.
Management of Respiratory Alkalosis
Treatment of respiratory alkalosis centers on correcting the underlying systemic cause or disorder. Close assessment of oxygenation status and correction of hypoxemia via oxygen administration is paramount. Acute hyperventilation syndrome often is treated simply by having the patient breathe into a paper bag. To prevent high altitude-associated respiratory alkalosis, slow ascent to allow for acclimatization is recommended; administra- 
Summary
• A wide array of conditions ultimately can lead to acid-base imbalance, and interpretation of acid-base disorders always involves a mix of art, knowledge, and clinical experience.
• Solving the puzzle of acid-base disorders begins with accurate diagnosis, a process requiring two tasks. First, acid-base variables in the blood must be reliably measured to determine the effect of multiple ions and buffers. Second, the data must be interpreted in relation to human disease to define the patient's acid-base status.
• History, physical examination, and additional laboratory testing and imaging help the clinician to identify the specific cause of the acid-base disturbance and to undertake appropriate intervention.
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